GNMX - Aevi Genomic Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.0090 (-5.77%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.1560
Bid0.1470 x 1000
Ask0.1496 x 800
Day's Range0.1400 - 0.1560
52 Week Range0.1100 - 1.2300
Avg. Volume717,225
Market Cap9.5M
Beta (3Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.2960
Earnings DateMay 11, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aevi Genomic Medicine, Inc. to Independent Bank Group Inc. is Fair to Shareholders

    NEW YORK, NY / ACCESSWIRE / December 10, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aevi Genomic Medicine, Inc. ("Aevi" ...

  • Aevi Genomic to be acquired in a deal valued at up to $22.6 million
    American City Business Journals

    Aevi Genomic to be acquired in a deal valued at up to $22.6 million

    Aevi's CEO Mike Cola will lead the combined the combined company, which which will have offices in Maryland and Wayne.

  • GlobeNewswire

    Cerecor to Acquire Aevi Genomic Medicine

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger agreement to acquire Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million at closing, plus contingent value rights, or CVRs, for up to an additional $6.5 million in subsequent milestone payments on clinical or regulatory successes, or both. Additionally, the Company is exploring strategic alternatives for its neurological assets as well as its one commercialized product Millipred®.

  • PR Newswire

    Aevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing Determination

    PHILADELPHIA, Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the Company until February 3, 2020 to gain and evidence compliance of the Nasdaq Capital Market continued listing requirements. In order to meet the Nasdaq Capital Market continued listing requirements, the Company must demonstrate a closing bid price of at least $1.00 for 10 prior consecutive trading days and both publicly announce and inform the Nasdaq Hearings Panel that the Company has stockholders' equity greater than $2.5 million on or before February 3, 2020.

  • PR Newswire

    Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody

    Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") ...

  • PR Newswire

    Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference

    PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present ...

  • PR Newswire

    Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor

    Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. PHILADELPHIA, July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization of Astellas' second generation mTORC1/2 inhibitor, ASP7486 (OSI-027). Aevi's initial focus of study with ASP7486 will be for congenital Lymphatic Malformations, which includes a number of rare and orphan diseases.


    These Four Healthcare Stocks are Surging with Potential

    CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Zacks Small Cap Research

    GNMX: ASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001

    On January 2nd Aevi (GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary endpoint of a statistically significant reduction of ADHD-RS at 6 weeks in either Part A (mGluR+ subjects) or Part B (mutation free subjects). As we have consistently stated in our coverage, given the largely positive results of SAGA and enrichment of ASCEND with only patients with mutations to nine select genes in the mGluR network, along with a pediatric weighting, we had expected ASCEND would prove successful. As a reminder about SAGA’s results (see link to our report), it did meet statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more, which is considered a clinical response).


    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • Benzinga

    The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

    Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.

  • PR Newswire

    Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

    PHILADELPHIA, Jan. 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.  AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.


    4 Pharma Stocks Getting a Boost on Thursday (12/20/18)

    CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.